Search Results - "Pharmacogenetics"

Suggested Topics within your search.
Refine Results
  1. 1
    Establishing precompetitive collaborations to stimulate genomics-driven product development workshop summary /

    Establishing precompetitive collaborations to stimulate genomics-driven product development workshop summary /

    Published 2011
    Subjects: “…Pharmacogenetics Congresses.…”
    An electronic book accessible through the World Wide Web; click to view
    Electronic Conference Proceeding eBook
    Save to List
    Saved in:
  2. 2
    Pharmacogenomics emphasis on clinical drug development /

    Pharmacogenomics emphasis on clinical drug development /

    Published 2012
    Subjects:
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  3. 3
    Chemogenomics

    Chemogenomics

    Published 2012
    Subjects:
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  4. 4
    Pharmacogenomics emphasis on clinical drug development /

    Pharmacogenomics emphasis on clinical drug development /

    Published 2012
    Subjects:
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  5. 5
    Pharmacogenomics emphasis on clinical drug development /

    Pharmacogenomics emphasis on clinical drug development /

    Published 2012
    Subjects:
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  6. 6
    Chemogenomics

    Chemogenomics

    Published 2012
    Subjects:
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  7. 7
    Chemogenomics

    Chemogenomics

    Published 2012
    Subjects:
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  8. 8
    Key drug discovery challenges in cardiovascular medicine

    Key drug discovery challenges in cardiovascular medicine

    Published 2014
    Table of Contents: “…Contents: Conventional therapeutic targets in CVD -- Identifying new targets (GWAS and association analysis) -- Validating new targets (Mendelian randomisation; IL6R, CHD and tocilizumab; sPLA2 inhibition and CHD prevention) -- Avoiding adverse effects (The ILLUMINATE trial, Torcetrapib and blood pressure) -- Making better use of existing drugs (Pharmacogenetics of Clopidogrel and CYP2C19) -- New approaches & drug development.…”
    Get full text
    Series (Genetics of cardiovascular disease)
    Series (Small molecule drug discovery)
    Electronic Video
    Save to List
    Saved in:
  9. 9
    Overview of clinical pharmacology in cancer part 1 of 2 /

    Overview of clinical pharmacology in cancer part 1 of 2 /

    Published 2017
    Subjects:
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  10. 10
    Key drug discovery challenges in cardiovascular medicine

    Key drug discovery challenges in cardiovascular medicine

    Published 2014
    Table of Contents: “…Contents: Conventional therapeutic targets in CVD -- Identifying new targets (GWAS and association analysis) -- Validating new targets (Mendelian randomisation; IL6R, CHD and tocilizumab; sPLA2 inhibition and CHD prevention) -- Avoiding adverse effects (The ILLUMINATE trial, Torcetrapib and blood pressure) -- Making better use of existing drugs (Pharmacogenetics of Clopidogrel and CYP2C19) -- New approaches & drug development.…”
    Get full text
    Series (Genetics of cardiovascular disease)
    Series (Small molecule drug discovery)
    Electronic Video
    Save to List
    Saved in:
  11. 11
    Key drug discovery challenges in cardiovascular medicine

    Key drug discovery challenges in cardiovascular medicine

    Published 2014
    Table of Contents: “…Contents: Conventional therapeutic targets in CVD -- Identifying new targets (GWAS and association analysis) -- Validating new targets (Mendelian randomisation; IL6R, CHD and tocilizumab; sPLA2 inhibition and CHD prevention) -- Avoiding adverse effects (The ILLUMINATE trial, Torcetrapib and blood pressure) -- Making better use of existing drugs (Pharmacogenetics of Clopidogrel and CYP2C19) -- New approaches & drug development.…”
    Get full text
    Series (Genetics of cardiovascular disease)
    Series (Small molecule drug discovery)
    Electronic Video
    Save to List
    Saved in:
  12. 12
    Overview of clinical pharmacology in cancer part 1 of 2 /

    Overview of clinical pharmacology in cancer part 1 of 2 /

    Published 2017
    Subjects:
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  13. 13
    Overview of clinical pharmacology in cancer part 1 of 2 /

    Overview of clinical pharmacology in cancer part 1 of 2 /

    Published 2017
    Subjects:
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  14. 14
    Arylamine N-acetyltransferases part 2 of 3 /

    Arylamine N-acetyltransferases part 2 of 3 /

    Published 2016
    Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  15. 15
    Arylamine N-acetyltransferases part 3 of 3 /

    Arylamine N-acetyltransferases part 3 of 3 /

    Published 2016
    Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  16. 16
    Arylamine N-acetyltransferases part 1 of 3 /

    Arylamine N-acetyltransferases part 1 of 3 /

    Published 2016
    Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  17. 17
    Arylamine N-acetyltransferases part 2 of 3 /

    Arylamine N-acetyltransferases part 2 of 3 /

    Published 2016
    Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  18. 18
    Arylamine N-acetyltransferases part 3 of 3 /

    Arylamine N-acetyltransferases part 3 of 3 /

    Published 2016
    Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  19. 19
    Arylamine N-acetyltransferases part 1 of 3 /

    Arylamine N-acetyltransferases part 1 of 3 /

    Published 2016
    Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:
  20. 20
    Arylamine N-acetyltransferases part 2 of 3 /

    Arylamine N-acetyltransferases part 2 of 3 /

    Published 2016
    Table of Contents: “…Contents: Mechanism of action -- Reaction substrates -- Isoform substrate profiles -- Isoenzymes NAT1 and NAT2 -- Regulation of gene expression -- Pharmacogenetics -- Phenotype/genotype correlation -- Ethnic variation -- Transgenic mouse models -- NAT protein structures -- NAT as a biomarker in breast cancer -- NAT inhibitors as diagnostic agents -- NAT in mycobacteria -- NAT inhibitors as an approach to potential anti-tubercular agents.…”
    Get full text
    Series
    Electronic Video
    Save to List
    Saved in:

Search Tools: